Article Text
Abstract
The current SARS-CoV-2 pandemic has killed thousands across the world. SARS-CoV-2 is the latest but surely not the last such global pandemic we will face. The biomedical response to such pandemics includes treatment, vaccination, and so on. In this paper, though, we argue that it is time to consider an additional strategy: the somatic (non-heritable) enhancement of human immunity. We argue for this approach and consider bioethics objections we believe can be overcome.
- clinical ethics
- enhancement
- ethics
- genetic engineering
Data availability statement
There are no data in this work.
Statistics from Altmetric.com
Data availability statement
There are no data in this work.
Footnotes
Twitter @cohenProf
Contributors Both authors contributed equally to the writing of the submitted manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy
- Passive and active immunity in infants born to mothers with SARS-CoV-2 infection during pregnancy: prospective cohort study
- SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report
- COVID-19 and liver disease
- Ethics of genomic passports: should the genetically resistant be exempted from lockdowns and quarantines?
- Risk of COVID-19 re-infection and its predictors (CORES): protocol for a community-based longitudinal cohort study in Vellore, India
- EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update
- Why ‘one size fits all’ is not enough when designing COVID-19 immunity certificates for domestic use: a UK-wide cross-sectional online survey
- Critical role of diagnostic SARS-CoV-2 T cell assays for immunodeficient patients
- COVID-19 vaccine hesitancy and vaccine passports: a cross-sectional conjoint experiment in Japan